Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on May 30, 2017 in Multiple Myeloma | 0 comments

In a nutshell

This study compared two induction therapy regimens before high-dose chemotherapy and stem cell (immature blood cell) transplantation (SCT) in patients with multiple myeloma. The authors concluded that the combination of bortezomib (Velcade), thalidomide (Thalomid), and dexamethasone (Ozurdex) was more effective than bortezomib, cyclophosphamide (Cytoxan), and dexamethasone.

Some background

The standard treatment for patients under the age of 66 with multiple myeloma is induction therapy to induce remission, followed by high-dose chemotherapy and SCT. Prior studies have shown that bortezomib-based induction is very effective. One standard option is now bortezomib combined with a treatment that stimulates the immune system (thalidomide) and the steroid dexamethasone (VTD). Another option is bortezomib and dexamethasone combined with the chemotherapy cyclophosphamide (VCD). It is not clear which combination is more effective.

Methods & findings

This study included 340 patients who were randomly assigned to induction therapy with VTD (170 patients) or VCD (170 patients). Patients were treated for at least 4 cycles.

After 4 cycles, 66.3% of VTD patients achieved at least a very good partial response (little or no sign of disease), compared to 56.2% of VCD patients. There was no significant difference in the rate of complete response (no sign of disease). 92.3% of VTD patients responded to treatment, compared to 83.4% of VCD patients.

Patients treated with VCD had higher rates of low red blood cell, white blood cell, and platelet levels. The risk of peripheral neuropathy (tingling and pain in the hands or feet) was higher with VTD. 

The bottom line

This study concluded that VTD therapy may be more effective than VCD before high-dose chemotherapy and SCT. 

Published By :

Blood

Date :

May 26, 2016

Original Title :

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial.

click here to get personalized updates